Clinical Trial Update: SP16 as a Therapeutic for COVID-19 Induced ARDS [Phase 1]

View source ↗

Summary

Phase 1 trial of SP16 for COVID-19-induced acute respiratory distress syndrome has been terminated by Serpin Pharma, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia
• Respiratory Distress Syndrome

Drugs mentioned

• SP16

Snippet

Sponsor: Serpin Pharma, LLC | Conditions: SARS CoV 2 Infection, Pneumonia | Phase 1 | Status: TERMINATED